Reasons For ZOMETA® | Patient Case Study – Multiple Myeloma

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Multiple Myeloma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Multiple Myeloma Patient Case Study – Marie

Marie T.

Aged 62 years
Lives and works on a family farm
Enjoys walking her dogs with her husband

Page

1 2

As new treatments extend survival, the threat of an SRE increases
in patients like Marie

The median survival for patients with multiple myeloma is nearly 4 years⁴
In patients with multiple myeloma and osteolytic disease, the median time to first SRE
is only 9 months⁵

Median time to first SRE vs median survival in multiple myeloma^4,5

ZOMETA®: Median time to first SRE vs. Survival time in multiple myeloma patients

*Median survival for patients diagnosed after 1996.

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

As new treatments extend survival, the threat of an SRE increasesin patients like Marie

As new treatments extend survival, the threat of an SRE increases
in patients like Marie